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Background & Aims: Spontaneous clearance of chronic hepatitis C virus (HCV) infection 47 
(CHC) is rare. We conducted a retrospective case control study to identify rates and factors 48 
associated with spontaneous clearance of CHC. 49 
Methods: We defined a case as an individual who spontaneously resolved CHC, and a 50 
control as an individual that remained chronically infected. We used data obtained on HCV 51 
testing between 1994 and 2013 in the West of Scotland to infer case/control status. 52 
Specifically, untreated patients with ≥ 2 sequential samples positive for HCV RNA ≥ 6 53 
months apart followed by ≥ 1 negative test, and those with ≥ 2 positive samples ≥ 6 months 54 
apart with no subsequent negative samples were identified. Control patients were randomly 55 
selected from the second group (4/patient of interest). Case notes were reviewed and patient 56 
characteristics obtained.  57 
Results: 25,113 samples were positive for HCV RNA, relating to 10,318 patients. 50 cases of 58 
late spontaneous clearance were identified, contributing 241 person-years follow-up. 2518 59 
untreated, chronically infected controls were identified, contributing 13,766 person-years 60 
follow-up, from whom 200 controls were randomly selected. Spontaneous clearance was 61 
positively associated with female gender, hepatitis B co-infection, younger age at infection 62 
and lower HCV RNA load. Spontaneous clearance was negatively associated with current 63 
intravenous drug use. The incidence rate of spontaneous clearance was 0.36/100 person-years 64 
follow-up, occurring after a median 50 months diagnosis.  65 
Conclusions: Spontaneous clearance of CHC occurs infrequently but is associated with 66 
identifiable host and viral factors. More frequent RNA monitoring may be appropriate in 67 





Hepatitis C virus (HCV) is an enveloped, positive sense, single stranded RNA virus which 71 
causes both acute and chronic hepatitis [1, 2]. Chronic HCV infection (CHC) is a global 72 
public health problem, estimated to affect approximately 185 million individuals worldwide 73 
and 37,000 persons in Scotland  [3]. Chronic hepatitis C develops in around 75% of people 74 
who acquire HCV infection, and it is defined as viral persistence beyond six months post 75 
exposure [3, 4].  76 
Spontaneous clearance of HCV in the acute phase (<6 months) occurs in around 20-40% of 77 
people who acquire HCV infection [2, 5]. Predictors of clearance remain poorly elucidated, 78 
however host factors, including gender [2, 6-8] and immune response [9], and viral factors, 79 
such as HCV genotype and quasispecies diversity [2], appear to be important. Host genetics 80 
are relevant, and the strongest host factor associated with clearance is a favourable 81 
interleukin-28B (IL28B) gene polymorphism [2, 8, 10]. 82 
Spontaneous clearance of HCV in the chronic phase is less well understood [11]. It has been 83 
reported in the literature following superinfection with hepatitis B virus (HBV) [12, 13] or 84 
following hepatitis delta virus (HDV) superinfection of human immunodeficiency virus 85 
(HIV)-HBV co-infected subjects [14].  Case reports have also described clearance following 86 
the withdrawal of immunosuppressive medication [15], in the context of liver transplantation 87 
or surgery [16, 17], following the development of hepatocellular carcinoma [18] and during 88 
pregnancy/parturition [19, 20]. Additionally, spontaneous HCV RNA negativity has been 89 
described in HIV-HCV co-infected patients, including those with hepatic decompensation, 90 
following initiation or optimisation of antiretroviral therapy [21-23]. 91 
Host factors may be important predictors of clearance in the chronic phase as well as the 92 
acute phase; Raghuraman et al reported a case of HCV clearance at 65 weeks post infection 93 
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which was associated with reversal of T cell exhaustion and the appearance of neutralising 94 
antibodies [24] and two recent studies looking at HIV-HCV co-infected patients found that 95 
late clearance was associated with a favourable IL28B-CC genotype [5, 23]. However, 96 
interpretation of these studies is limited by the small number of cases. 97 
We sought to establish the incidence and factors associated with spontaneous clearance of 98 


















Patients and methods 115 
Study design and population: 116 
The West of Scotland Specialist Virus Centre (WoSSVC) is part of the NHS Greater 117 
Glasgow & Clyde Health Board (NHSGGC) which serves a population of > 1 million. Of the 118 
35474 cases of HCV antibody positivity diagnosed in Scotland as of December 2013, 14076 119 
(40%) reside within NHSGGC [25]. The WoSSVC provides the majority of the diagnostic 120 
virology service for the West of Scotland and is the sole provider of HCV RNA testing. Data 121 
were obtained from the WoSSVC on HCV testing over a 20 year period between 1994 and 122 
2013. The study followed a retrospective case-control design; cases were individuals who 123 
spontaneously resolved CHC, and controls were individuals who did not.   124 
Identifying cases and controls: 125 
All patients must have been tested on either serum or dried blood spot (DBS) for HCV RNA 126 
as part of their clinical care. Patients with a minimum of 2 sequential samples positive for 127 
HCV RNA at least 6 months apart, followed by at least one negative test for HCV RNA, 128 
were identified. These patients were linked with national treatment data obtained from the 129 
Scottish Hepatitis C Clinical Database. This database is held by Health Protection Scotland 130 
(HPS) and contains clinical and treatment data for HCV infected patients attending outpatient 131 
specialist clinics across Scotland [26]. Patients with a history of HCV treatment were then 132 
excluded to create a cohort of individuals with potential spontaneous clearance of chronic 133 
HCV. Clinical records of potential spontaneous clearers were reviewed to confirm the clinical 134 
scenario. Individuals in the spontaneous clearance group with > 1 negative HCV RNA 135 
sample were subcategorised as ‘confirmed’ clearers. 136 
Patients with 2 positive HCV RNA samples at least 6 months apart with no subsequent 137 
negative samples were identified as our comparison group. To create a control group of 138 
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chronically infected patients, individuals were randomly selected from the comparison group 139 
using number generation with a frequency of 4 controls per patient of interest. 140 
Clinical, demographic and exposure data on cases and controls: 141 
Demographic patient data (age at infection, sex, ethnicity, alcohol intake, body mass index 142 
(BMI), source of infection), HCV markers (liver enzymes, HCV genotype, IL28B genotype, 143 
HCV RNA and history of cirrhosis), HIV, HBV and HDV serostatus and IL28B genotype 144 
were obtained from the Scottish Hepatitis C Clinical Database, augmented by case note 145 
review. Where available, biochemical and haematologic variables were recorded at the time 146 
of the last positive HCV RNA test for all patients, and concurrently with the first negative 147 
HCV RNA test for spontaneous clearers. The date of HCV clearance was estimated using the 148 
midpoint between the time at which the last positive HCV RNA and the first negative HCV 149 
RNA samples were collected. Duration of diagnosis (which serves as a proxy of duration of 150 
infection) was calculated as the interval between the first positive HCV RNA and the time of 151 
HCV clearance for spontaneous clearers; for the control group this was defined as the interval 152 
between the first positive and the last positive HCV RNA results. Follow up was censored at 153 
the last positive HCV RNA test for the control group. Clinical records for case patients were 154 
reviewed and data were collected on hospitalisations or acute events in the 12 months prior to 155 
clearance. 156 
Incidence of spontaneous resolution of CHC: 157 
The incidence density rate of spontaneous clearance of CHC amongst untreated individuals 158 
was calculated as the number of cases of spontaneous clearance over the total number of 159 





Laboratory testing: 163 
All patients had been tested for HCV RNA as part of their clinical care. Viral load samples 164 
logged as ‘positive’ or ‘detectable’ were recorded as the upper limit of sensitivity for the 165 
given assay. Patients underwent HCV genotyping as part of their routine clinical care.  166 
Statistical analysis: 167 
Continuous variables are expressed as medians and interquartile ranges, and categorical 168 
variables are recorded as number and percentages. Categorical variables were compared 169 
using chi-square testing and continuous variables were analysed using the exact Wilcoxon 170 
Mann-Whitney test. P values are 2-sided and values of <0.05 were considered significant. 171 
The IBM SPSS Statistics 22 software was used for data analysis and missing variables were 172 














Derivation of final sample (Figure 1): 185 
A total of 25,113 samples were positive for HCV RNA, relating to 10,318 patients. Of these, 186 
1430 patients had 2 sequential positive results followed by a negative result. Following 187 
linkage to the Scottish Hepatitis C Clinical Database 1314 patients were identified as 188 
treatment experienced and were thus excluded, leaving 116 patients of interest. Ten patients 189 
were excluded following case note review as examination of full laboratory data showed that 190 
the HCV RNA positive samples were not sequential, suggesting 2 or more episodes of 191 
spontaneous clearance during acute infection rather than spontaneous clearance of CHC.  A 192 
further 48 patients had exposure to HCV treatment that had not yet been recorded on the 193 
national database. For 7 patients, patient identifiers held in the database did not link with a 194 
clinical record. One patient had been incorrectly coded as negative, but on review of the 195 
laboratory data was found to have quantifiable HCV RNA. After these exclusions, 50 case 196 
patients remained and were included in downstream analysis, contributing 241 person-years 197 
follow up. Two patients were classified as spontaneous clearers solely on the basis of DBS 198 
testing, 1 of whom went on to have a positive serum HCV RNA test in the absence of 199 
ongoing risk exposure. A further 2 patients who were classified as spontaneous clearers on 200 
the basis of serum HCV RNA testing developed HCV RNA positivity > 1 year post probable 201 
clearance; 1 patient admitted to ongoing IDU. Twenty-seven patients went on to have at least 202 
1 further negative HCV RNA test (26 serum samples and 1 DBS) and were subcategorised as 203 
‘confirmed’ clearers. 204 
For the comparison group, 3329 patients with 2 positive HCV-RNA samples at least 6 205 
months apart with no subsequent negative samples were identified of whom 955 were 206 
treatment experienced. The remaining 2374 were untreated, contributing 13766 person-years 207 
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follow up. Our control population comprised 200 randomly selected patients from this 208 
untreated cohort.  209 
Incidence of spontaneous clearance of CHC: 210 
The overall incidence density rate of spontaneous clearance of CHC amongst the untreated 211 
patient population was 0.36 per 100-person-years follow up. When restricting the analysis to 212 
patients with ‘confirmed’ clearance, the incidence rate was 0.19 per 100-person-years follow 213 
up.  214 
Characteristics of cases and controls: 215 
Table 1 summarises the main demographic and clinical characteristics of the study 216 
populations. The majority of patients were white, with a history of IDU as the risk factor for 217 
acquisition of HCV. There was a similar incidence of Gt1 and genotype 3 (Gt3) infections. 218 
There were no significant differences in HCV genotype, ethnicity or risk group between the 219 
two populations. Ongoing IDU was positively associated with chronicity of infection 220 
(p=0.034).  221 
Patients who spontaneously cleared CHC were more likely to be female (p = 0.001) and to 222 
have been diagnosed at a younger age (28.5 years vs. 33 years; p = 0.022). Median age at 223 
diagnosis in females was not significantly different between the two groups (27 years vs. 31.5 224 
years; p=0.144). The age at which males and females were diagnosed in each group was 225 
similar (cases, p=0.200; controls, p=0.108). 226 
There was no difference in the distribution of duration of diagnosis between groups (median 227 
duration 50 months v 50 months; p= 0.854) (Figure 2). The minimum duration of diagnosis in 228 
the spontaneous clearance group was 9 months and the maximum duration was 182 months, 229 
compared with 7 months and 195 months in the comparator group. As spontaneous clearance 230 
may be more likely in early infection, a subgroup analysis was performed for case patients 231 
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(n=41) and control patients (n=144) with at least 24 months confirmed viraemia and showed 232 
identical findings (Supplementary data: Table 1). 233 
Median ALT levels were similar between cases and controls at the time of the last positive 234 
HCV RNA test (47.5 IU/L v 42.5 IU/L, p=0.560). There was a significant decrease in the 235 
ALT level between the last positive and the first negative HCV RNA test for case patients, 236 
providing further evidence of spontaneous clearance (47.5 IU/L v 20 IU/L, p<0.001). 237 
Of those subjects who had been tested, quantitative HCV RNA levels were significantly 238 
lower amongst cases versus controls (p<0.001) however spontaneous clearance in the context 239 
of high-level viraemia (>10000 IU/mL) was observed in 7 patients (Figure 3). IL28B 240 
genotyping was performed on 1 case patient; this patient was found to carry the IL28B-CC 241 
allele. 242 
27 of the cases had repeated negative RNA testing. Demographic and virologic 243 
characteristics of these are compared with controls in Table 2. On analysis of this more 244 
strictly defined cohort of spontaneous clearers, only female gender (p=0.006) and a lower 245 
median HCV viral load (p=0.001) remained significantly associated with clearance of CHC. 246 
Co-infection with HIV and hepatotropic viruses: 247 
Amongst those tested, patients who spontaneously cleared CHC were significantly more 248 
likely to be hepatitis B surface antigen (HBsAg) positive (5/48 (10.4%) vs 0/99 (0%); 249 
p<0.001). Eight case patients and 28 patients in the control group were positive for hepatitis 250 
B core antibody and negative for HBsAg indicating past infection. One HBsAg+ patient was 251 
co-infected with hepatitis delta virus. Rates of HIV IgG positivity were similar between the 252 
two groups (p=0.518). 253 
Acute events: 254 
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In 5 patients, 4 of whom had documentation of ongoing alcohol abuse, spontaneous clearance 255 
of CHC followed admission to hospital with decompensated liver disease. In 2 of these cases 256 
there was intercurrent sepsis and in 1 case the patient was admitted twice; once as a result of 257 
a staggered paracetamol overdose and several months later due to alcoholic hepatitis with 258 
queried spontaneous bacterial peritonitis. The abstinent patient decompensated due to gram 259 
negative bacteraemia. Of the decompensated patients, two had significant ALT rises (>5 260 


















This is the largest cohort of patients with evidence of spontaneous clearance of chronic HCV 277 
infection studied to date.  We have demonstrated that spontaneous clearance of CHC is rare, 278 
with an incidence rate of 0.19 – 0.36 per 100-person-years follow up. We found that 279 
spontaneous clearance of CHC was associated with female gender, HBsAg positivity, 280 
younger age at diagnosis and lower HCV RNA titres. It was negatively associated with 281 
current IDU. We observed that a proportion of cases occurred in the context of significant 282 
intercurrent illness and hepatic decompensation. 283 
The incidence rate of spontaneous HCV clearance in our cohort is similar to that described in 284 
a previous Japanese study which demonstrated an annualized incidence rate of spontaneous 285 
CHC clearance of 0.5%/year/person and found that clearance was associated with milder 286 
liver disease [11].  In contrast, a recent study by Scott et al., [27] found that a significant 287 
percentage of Alaska Natives with CHC experienced HCV RNA negativity, corresponding to 288 
a rate of 1.15 per 100 persons per year. This variation in rates of spontaneous clearance may 289 
reflect the different genetic background of the study populations together with different 290 
incidences of factors associated with clearance of CHC.  In addition, repeat HCV RNA 291 
testing in patients with established CHC in whom treatment is not immediately anticipated is 292 
performed rarely in our clinical practice, in accordance with international guidelines [4]. 293 
Infrequent repeat testing of HCV RNA may have led to an underestimate of the true 294 
incidence of spontaneous clearance in our cohort.  295 
Concurrent with our study, Scott et al., [27] found that spontaneous HCV clearance was 296 
associated with a lower HCV viral load and a trend towards younger age at infection. Older 297 
age at acquisition is independently associated with a faster progression to fibrosis, even when 298 
controlling for duration of infection [28], and children who are vertically infected appear to 299 
14 
 
have a very slow progression to cirrhosis [29]. The presence of significant fibrosis is 300 
associated with a poorer response to HCV therapy [4] and may be negatively associated with 301 
spontaneous clearance of CHC [11]. The reasons for the importance of age as a predictor of 302 
progressive fibrosis are undetermined, but may relate to changes in immune function and 303 
reduced hepatic blood flow [30].  304 
Female sex was significantly associated with spontaneous clearance of CHC in our study. 305 
This result remained significant when restricting the analysis to ‘confirmed’ clearers. These 306 
results mirror findings in the acute setting [2, 6-8], and are supported by data from Scott et 307 
al., [27] who found that all patients in their cohort with late sustained HCV RNA negativity 308 
were female. It has been postulated that gender-based differences in immunity may underlie 309 
the association between female sex and acute spontaneous clearance [2], and the same may 310 
hold true for clearance in the chronic setting. Additionally, male sex is associated with a 311 
faster progression to cirrhosis, even after controlling for age, duration of infection, alcohol 312 
intake and metabolic factors [31, 32]. It is possible that male gender was associated with 313 
increased disease severity in our study, and therefore a lower rate of clearance. Furthermore, 314 
Grebely et al., [2] demonstrated that the effect of IL28B and HCV genotype on clearance in 315 
the acute phase was greater among females than males. IL28B-CC genotype has also been 316 
associated with spontaneous clearance of HCV in HCV-HIV co-infected patients (5, 24), a 317 
finding we are unable to confirm due to infrequent testing amongst our cases. 318 
Gt1 and Gt3 were equally distributed in our cohort, reflecting the distribution in Scotland 319 
[25]. We did not find an increased likelihood of spontaneous clearance associated with Gt1 320 
infection, as has previously been described in both the acute and the chronic setting [2, 27]. 321 
However, as only a third of patients in our cohort had viral genotyping performed it is 322 
possible that this null result reflects limited statistical power.  323 
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Hepatitis B surface antigen positivity was significantly associated with spontaneous clearance 324 
of CHC (p = 0.001). HCV clearance in the context of HBV superinfection has been described 325 
in several case reports [12, 13] and may occur as a bystander effect of antiviral cytokine 326 
release [13]. It has been suggested that release of type 1 interferons (IFN) from the liver 327 
during acute infection may contribute to clearance [33] and that HBV may monopolise the 328 
synthetic machinery of the hepatocyte, thus interrupting the HCV replication cycle [33].  329 
Despite the negative association previously described between fibrosis and spontaneous 330 
clearance of CHC [11], one third of our case patients had a diagnosis of cirrhosis. 331 
Additionally, we identified a unique cohort of patients who cleared HCV following 332 
decompensation of their cirrhosis, most commonly in the context of alcohol excess and 333 
bacterial infection. The mechanisms underlying spontaneous clearance in this setting are 334 
unclear. Cirrhosis is associated with a reduction in the number of functional hepatocytes, 335 
potentially limiting viral replication and whilst HCV RNA quantification was performed too 336 
infrequently in our study to explore this hypothesis, patients with cirrhosis have been found 337 
to have lower HCV viral loads than non-cirrhotic subjects in a large Scottish mixed infection 338 
database (unpublished data [34]). Furthermore, cirrhosis is associated with immune 339 
dysregulation and predisposition to bacterial infection [35]. Bacterial translocation occurs as 340 
a result of intestinal bacterial overgrowth and increased intestinal permeability, and results in 341 
endotoxaemia [35, 36]. Bacterial lipopolysaccharide (LPS) triggers production of 342 
inflammatory cytokines, including IFN-γ from hepatic lymphocytes, resulting in acute 343 
hepatic injury. Chronic alcohol ingestion enhances immune cell sensitivity to LPS resulting 344 
in increased production of inflammatory cytokines [37]. We hypothesise that HCV RNA 345 
clearance may occur in this setting as a result of non-specific stimulation of the immune 346 
system on a background of lower baseline viral load [27]. In support of this, two of the 347 
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decompensated patients in our study had significant hepatitis flares preceding clearance 348 
suggesting the development of a vigorous Th1 cytopathic immune response.  349 
Finally, we present the tentative finding that ongoing IDU is negatively associated with 350 
spontaneous clearance of CHC. People who inject drugs (PWIDs) are at risk of superinfection 351 
with distinct HCV strains which may negatively impact the likelihood of spontaneous 352 
clearance [38, 39]. We also accept the possibility that a high HCV re-infection rate post 353 
clearance amongst PWIDs may be masking the incidence of spontaneous clearance in our 354 
cohort [6, 40]. However, one study based in NHSGGC reported a trend towards a lower 355 
incidence of re-infection post spontaneous clearance [41] as described in previous studies 356 
[42].  357 
There are a number of limitations to our study as a consequence of its observational and 358 
retrospective design.  Our study is strengthened by the inclusion of patients presenting and 359 
followed up over two decades. Inherent in this however, is considerable variation in the 360 
utilisation of different laboratory tests over time, reflecting changing advice from clinical 361 
guidelines [43, 44] and the development and introduction of new technologies.  As a 362 
consequence of the missing data, multivariate analysis was not deemed appropriate and 363 
statistical inferences must be interpreted with caution. 364 
We accepted HCV RNA testing on both serum and DBS in our study design to increase our 365 
study population. DBS testing may increase the uptake of screening in PWIDs, in whom 366 
venepuncture is often difficult and who may be less likely to attend clinic [45, 46]. However, 367 
HCV RNA testing on DBS has reduced sensitivity compared to the serum assay; one patient 368 
in our cohort who was classified as a spontaneous clearer on the basis of DBS HCV RNA 369 
testing was found to have detectable HCV RNA on a subsequent serum sample. Additionally, 370 
the sensitivity of the serum quantitative HCV RNA assays varied over the course of follow 371 
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up (supplementary data) and earlier samples may have been more likely to be falsely 372 
negative. Additionally, fluctuating and low level viraemia is common in the early stages of 373 
infection. As we relied on only one negative HCV RNA for the definition of spontaneous 374 
clearance, it is possible that we misclassified these patients as spontaneous clearers. 375 
However, restricting the analysis to patients with at least 24 months confirmed infection did 376 
not change our findings and the normalisation of liver biochemistry provides further support 377 
for clearance. 378 
Follow up of patients with presumed late spontaneous clearance was poor; only 60% of 379 
spontaneous clearers had follow up HCV-RNA testing performed at any time point to 380 
confirm clearance. To address this limitation we performed an additional analysis of patients 381 
with persistent HCV RNA negativity over time and found that only female gender and low 382 
HCV viral load remained significant. 383 
We used age at diagnosis as a surrogate marker for age at infection. Many patients self-384 
identified as having been at risk of exposure to HCV many years before they were first tested 385 
and therefore it is likely that we overestimated the true age at infection. Also, for many case 386 
patients there was a considerable duration between the last positive and the first negative 387 
HCV PCR, making it difficult to ascertain the true date of HCV clearance.  388 
Finally, HCV RNA testing rates may be subject to bias. Repeat HCV RNA testing in CHC is 389 
only recommended in patients for whom treatment is anticipated [4]. Although we allowed 390 
testing on DBS to increase our study population, certain patient groups may have been less 391 
likely to have been tested, including patients with chaotic lifestyles who are not engaged in 392 
care, or patients with contraindications to therapy. However, despite the methodological 393 
drawbacks inherent in a retrospective study, the biological plausibility of our results and 394 
concordance with the precedent in the literature lead us to believe that our results are sound. 395 
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We conclude that spontaneous clearance of CHC is more common in females and patients 396 
with a low HCV viral load, and that previously described factors including superinfection 397 
with HBV and younger age at infection may play a role. We report novel findings of a 398 
negative association with ongoing IDU, and describe a cohort of spontaneous clearance in the 399 
context of decompensated liver disease.  Further work is required to identify the mechanisms 400 
underlying spontaneous clearance of chronic infection. Given that such clearance may occur 401 
after a prolonged duration of chronic infection, more regular serum HCV-RNA monitoring 402 
may be warranted, particularly in females, HBV co infection, patients with low level viraemia 403 
and those with decompensated liver disease.  404 
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Table 1: Univariate association between case-control status and demographic/clinical 549 
factors 550 





Male sex [n (%)] 19 (38) 129 (65) 0.001 
Median age at diagnosis  
[years (IQR)] 
29 (25-36) 33 (28-38) 0.022 
Ethnic group [n (%)] 
     White 










Risk group [n (%*)] 
     Intravenous drug use 
     Other 













HCV genotype [n (%*)] 
     1 
     2 
     3 
















Serum HIV IgG [n(%*)] 
     Positive 
     Negative 










Serum HBsAg [n (%*)] 
     Positive 
     Negative 










Current IDU [n (%*)] 
     Yes 
     No 










History of alcohol 
excess/ALD [n (%*)] 
     Yes 
     No 












Cirrhosis [n (%*)] 
     Yes 
     No 













Median duration of 
diagnosis [months (IQR)] 
50 (31-81) 50 (19-103) 0.854 
HCV VL (IU/ml) 
     Median 
     Interquartile range 
 
1000† 
1000 - 83293 
 
341142† 
59496 - 1517864 
<0.001 
*Percentage related to the actually recorded data; missing data handled by listwise deletion 551 











Male sex [n (%)] 10 (37) 129 (65) 0.006 
Median age at diagnosis  
[years (IQR)] 
29 (25-37) 33 (28-38) 0.142 
Ethnic group [n (%)] 
     White 










Risk group [n (%*)] 
     Intravenous drug use 
     Other 













HCV genotype [n (%*)] 
     1 
     2 
     3 
















Serum HIV IgG [n (%*)] 
     Positive 
     Negative 










Serum HBsAg [n (%*)] 
     Positive 
     Negative 










Current IDU [n (%*)] 
     Yes 
     No 










History of alcohol 
excess/ALD [n (%*)] 
     Yes 
     No 












Cirrhosis [n (%*)] 
     Yes 
     No 













Median duration of 
diagnosis [months (IQR)] 
46 (29-76) 50 (19-103) 0.593 
HCV VL (IU/ml) 
     Median 
     Interquartile range 
 
1000† 
763 - 131242 
 
341142† 
59496 - 1517864 
0.001 
*Percentage related to the actually recorded data; missing data handled by listwise deletion 556 





Figure legends 560 
Figure 1. Derivation of case and control patient cohorts 561 
Figure 2. Box-whisker plot of duration of diagnosis by group 562 





percentile, whiskers range and horizontal lines represent the median. Outliers are shown as 564 
circles. 565 
Figure 2. Changes in HCV RNA levels against time since diagnosis for individuals 566 
showing spontaneous clearance of HCV RNA 567 
Panel A: Changes in HCV RNA against time since diagnosis for all individuals with PCR 568 
results available (n=19). Point 0 represents the date of diagnosis. 569 

































*Patients excluded following linkage to treatment data held in the Scottish Hepatitis C 601 








samples positive for 
HCV RNA (n=10318) 
 
Two sequential +ve 
samples followed by 
≥ 1 –ve (n=1430) 
 
Two sequential +ve 
HCV RNA samples 














Excluded following case 
note review (n=66): 
 treatment 
experienced (n=48) 
 results suggest ≥ 2 
episodes of acute 
clearance (n=10) 
 did not link to 
clinical record (n=7) 





comparison group at 
frequency of 4 per case 
Control group 
(n=200) 
Cases of spontaneous 
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